AstraZeneca Boosts EU Vaccine Supply

The transcript discusses the challenges faced by the EU in vaccine distribution, focusing on issues with AstraZeneca regarding unfair treatment and production capacity. It highlights the EU's negotiation strategies, the benefits of a single European framework, and compares the EU's approach to the UK's in terms of vaccine authorization and strategy.

What were the consequences of AstraZeneca's decision to not store vaccines as requested by the EU?

What was the EU's strategy regarding vaccine contracts compared to the UK?

How did the EU's approach to vaccine authorization differ from that of the UK?